Bivalirudin
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Bivalirudin Product Information
Bivalirudin is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Bivalirudin. The product is supplied by Clearsynth under CAT No. CS-O-06181.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Bivalirudin
CAS No.
128270-60-0
CAT No.
CS-O-06181
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C₉₈H₁₃₈N₂₄O₃₃
Molecular Weight
2180.32
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Bivalirudin is supplied with detailed characterization data compliant with regulatory guideline. Bivalirudin can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Bivalirudin.
Overview
"For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes"
Synonyms
Bivalirudin
Application Notes
"For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes"
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.